Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -194.58% | -68.46% | 23.48% | -49.80% | |
| Total Depreciation and Amortization | 46.15% | 7.14% | 650.00% | 766.67% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 196.12% | 100.90% | -84.87% | 276.98% | |
| Change in Net Operating Assets | 255.33% | -507.44% | -18.89% | 39.96% | |
| Cash from Operations | -92.68% | -273.72% | -63.54% | -7.81% | |
| Capital Expenditure | -- | 90.83% | 94.67% | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | 90.83% | 94.67% | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 235.77% | -- | 396,970.24% | 321.54% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 235.77% | -100.50% | 737.39% | -99.28% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -92.09% | -116.67% | 984.54% | -365.73% | |